References
- Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145–51.
- Stojanovich L. Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev 2006;5:344–8.
- Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, . International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309–11.
- Espinosa G, Cervera R, Font J, Asherson RA. The lung in the antiphospholipid syndrome. Ann Rheum Dis 2002;61:195–8.
- Cervera R; CAPS Registry Project Group. Catastrophic antiphospholipid syndrome (CAPS): update from the ‘CAPS Registry’. Lupus 2010;19:412–18.
- Stojanovich L, Marisavljevic D, Rovensky J, Djokovich A, Kozakova D, Milinic N. Clinical and laboratory features of the catastrophic antiphospholipid syndrome. Clin Rev Allergy Immunol 2009;36:74–9.
- Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
- Petri M, Buyon J, Skovron ML. Reliability of SELENA, SLEDAI and flare as clinical trial outcome measures. Arthritis Rheum 1998;41:S218.
- Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, . Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8.
- Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, . Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353–65.
- Asherson RA, Pierangeli SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis 2007; 66:429–32.
- Petri M, Rheinschmidt M, Whiting-O’Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med 1987; 106:524–31.
- Bertolaccini ML, Gomez S, Pareja JF, Theodoridou A, Sanna G, Hughes GR, . Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 2005;64:1639–43.
- Neville C, Rauch J, Kassis J, Chang ER, Joseph L, Le Comte M, . Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphosphospholipid antibodies. Thromb Haemost 2003;90:108–15.
- Marai I, Levim Y, Godard G, Shoenfeld Y. Following 90 patients with antiphospholipid syndrome with antibody levels and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population. Harefuah 2001;140: 495–500.